Vitamin D metabolites and growth hormone therapy in uraemic rats: The short-term effect on growth failure and hyperparathyroidism

Satoshi Hisano, Craig Langman, Kay Latta, Richard J. Krieg, James C.M. Chan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of our study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (D), 22-oxacalcitriol (O) or recombinant human growth hormone (GH) on growth failure and hyperparathyroidism in 5/6 nephrectomized uraemic (Ur) rats. Seven groups of rats were studied: (i) sham controls (SC; n=6); (ii) Ur controls (UrC; n=8); (iii) Ur treated either with D (UrD; n=7); (iv) O (UrO, n=8); (v) GH (UrGH; n=7); (vi) D+GH (UrDGH; n=9); or (vii) O+GH (UrOGH; n=7). For 14 days, D and O were administered intraperitoneally daily at 30 ng/kg per day and GH subcutaneously daily at 1.3 i.u./day. Four weeks after 5/6 nephrectomy, plasma creatinine (Cr), plasma and urine calcium (Ca), plasma phosphate (P), ratio of urine Ca/urine Cr, amino-terminal parathyroid hormone (PTH; pg/mL) and Ca/dry bone weight in the left femur (mg/g) were measured. Uraemic controls, UrD, UrO and UrDGH rats were lower in weight gain than SC rats over the study period, but linear growth was not retarded in any uraemic group. Plasma Cr was greatly increased in any Ur group as compared with SC group. Plasma Ca and P concentrations did not differ among each group. The ratio of urine Ca/ urine Cr in UrD and UrDGH groups was higher than SC, UrC and UrGH groups. The use of D or D+GH suppressed PTH, returning the level in these rats to the normal level of the SC rats, while the PTH concentrations in the UrO and UrOGH rats were less decreased. Bone Ca content was enhanced by D+GH and O+GH administration in comparison with UrC rats, but there was no difference in the bone Ca content between UrD and UrDGH rats, and between UrO and UrOGH rats. In conclusion, growth failure in weight was shown in uraemia, hut linear growth was not retarded in any uraemic group. 1,25 dihydroxyvitamin D3 and D plus GH successfully suppressed secondary hyperparathyroidism. Further studies are needed in order to elucidate the interactions on bone between vitamin D metabolites and GH.

Original languageEnglish (US)
Pages (from-to)247-252
Number of pages6
JournalNephrology
Volume2
Issue number4
DOIs
StatePublished - Jan 1 1996

Keywords

  • 1,25 dihydroxyvitamin D
  • 22-oxacalcitriol
  • Growth hormone
  • Growth retardation
  • Hyperparathyroidism
  • Uraemia

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Vitamin D metabolites and growth hormone therapy in uraemic rats: The short-term effect on growth failure and hyperparathyroidism'. Together they form a unique fingerprint.

Cite this